T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia
Abstract
:Simple Summary
Abstract
1. Introduction
2. The Tumor Microenvironment in Chronic Lymphocytic Leukemia: Supportive and Suppressive
3. Immunotherapy in CLL
3.1. Passive Immunotherapy in CLL
3.1.1. Anti-CD20 Monoclonal Antibodies
3.1.2. Immune-Checkpoint Inhibitors
3.1.3. Bispecific T Cell Engager Antibodies
3.1.4. Immunomodulatory Drugs
3.2. Active Immunotherapy
3.2.1. Vaccines
3.2.2. CAR-T Cells
3.3. Immunomodulation as an Off-Target Effect of B Cell Receptor Inhibitors
4. Why Does Immunotherapy Work for Some but Not All Patients?
5. T Cell Compartment Defects as Targets for Immunotherapy
5.1. Imbalances in T Cell Subpopulations and Functions
5.2. Defective Immune Synapse Formation
5.3. Functional Incapacitation as an Aspect of Terminal Differentiation?
6. Immunogenetic Cues Support the Existence of Specific Anti-CLL T Cell Responses
7. Concluding Remarks
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Bosch, F.; Dalla-Favera, R. Chronic lymphocytic leukaemia: From genetics to treatment. Nat. Rev. Clin. Oncol. 2019, 16, 684–701. [Google Scholar] [CrossRef]
- Guièze, R.; Wu, C.J. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood 2015, 126, 445–453. [Google Scholar] [CrossRef] [Green Version]
- Strefford, J.C. The genomic landscape of chronic lymphocytic leukaemia: Biological and clinical implications. Br. J. Haematol. 2015, 169, 14–31. [Google Scholar] [CrossRef]
- Quesada, V.; Ramsay, A.J.; Rodríguez, D.; Puente, X.S.; Campo, E.; López-Otín, C. The genomic landscape of chronic lymphocytic leukemia: Clinical implications. BMC Med. 2013, 11, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Landau, D.A.; Wu, C.J. Chronic lymphocytic leukemia: Molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013, 5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baliakas, P.; Jeromin, S.; Iskas, M.; Puiggros, A.; Plevova, K.; Nguyen-Khac, F.; Davis, Z.; Rigolin, G.M.; Visentin, A.; Xochelli, A.; et al. Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact. Blood 2019, 133, 1205–1216. [Google Scholar] [CrossRef] [Green Version]
- Landau, D.A.; Tausch, E.; Taylor-Weiner, A.N.; Stewart, C.; Reiter, J.G.; Bahlo, J.; Kluth, S.; Bozic, I.; Lawrence, M.; Böttcher, S.; et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015, 526, 525–530. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baliakas, P.; Hadzidimitriou, A.; Sutton, L.A.; Rossi, D.; Minga, E.; Villamor, N.; Larrayoz, M.; Kminkova, J.; Agathangelidis, A.; Davis, Z.; et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015, 29, 329–336. [Google Scholar] [CrossRef] [PubMed]
- Pastore, A.; Gaiti, F.; Lu, S.X.; Brand, R.M.; Kulm, S.; Chaligne, R.; Gu, H.; Huang, K.Y.; Stamenova, E.K.; Béguelin, W.; et al. Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nat. Commun. 2019, 10, 1–11. [Google Scholar] [CrossRef]
- Martín-Subero, J.I.; López-Otín, C.; Campo, E. Genetic and epigenetic basis of chronic lymphocytic leukemia. Curr. Opin. Hematol. 2013, 20, 362–368. [Google Scholar] [CrossRef] [PubMed]
- Raval, A.; Byrd, J.C.; Plass, C. Epigenetics in Chronic Lymphocytic Leukemia. Semin. Oncol. 2006, 33, 157–166. [Google Scholar] [CrossRef] [PubMed]
- Zent, C.S.; LaPlant, B.R.; Johnston, P.B.; Call, T.G.; Habermann, T.M.; Micallef, I.N.; Witzig, T.E. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL Cells into the circulation. Cancer 2010, 116, 2201–2207. [Google Scholar] [CrossRef] [PubMed]
- Bennett, F.; Rawstron, A.; Plummer, M.; De Tute, R.; Moreton, P.; Jack, A.; Hillmen, P. B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. Br. J. Haematol. 2007, 139, 600–604. [Google Scholar] [CrossRef]
- Burger, J.A. Nurture Versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia. Available online: http://ashpublications.org/hematology/article-pdf/2011/1/96/1494794/bep00111000096.pdf (accessed on 31 March 2021).
- Burger, J.A.; Gribben, J.G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. Semin. Cancer Biol. 2014, 24, 71–81. [Google Scholar] [CrossRef]
- Oliveira, G.B.; Pereira, F.G.; Metze, K.; Lorand-Metze, I. Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. Commun. Clin. Cytom. 2001, 46, 329–335. [Google Scholar] [CrossRef] [PubMed]
- Plander, M.; Seegers, S.; Ugocsai, P.; Diermeier-Daucher, S.; Iványi, J.; Schmitz, G.; Hofstädter, F.; Schwarz, S.; Orsó, E.; Knüchel, R.; et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009, 23, 2118–2128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lapieaux, L.; Delforfe, A.; Bron, P.; De Bruyn, C.; Slryckmans, P. Chronic lymphocytic leukemia (CLL) B-lymphocytes but not normal B-lymphocytes are rescued from apoptosis by contact with bone marrow stromal cells. Exp. Hematol. 1997, 25, 862. [Google Scholar] [CrossRef]
- Burger, J.A. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 2012, 24, 643–649. [Google Scholar] [CrossRef] [PubMed]
- Svanberg, R.; Janum, S.; Patten, P.E.M.; Ramsay, A.G.; Niemann, C.U. Targeting the tumor microenvironment in chronic lymphocytic leukemia. Haematologica 2021, 106. [Google Scholar] [CrossRef]
- Dubois, N.; Crompot, E.; Meuleman, N.; Bron, D.; Lagneaux, L.; Stamatopoulos, B. Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. Front. Oncol. 2020, 10, 1–19. [Google Scholar] [CrossRef]
- Caligaris-Cappio, F.; Bertilaccio, M.T.S.; Scielzo, C. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin. Cancer Biol. 2014, 24, 43–48. [Google Scholar] [CrossRef]
- van Attekum, M.H.A.; Eldering, E.; Kater, A.P. Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. Haematologica 2017, 102, 1469–1476. [Google Scholar] [CrossRef] [Green Version]
- Arruga, F.; Gyau, B.B.; Iannello, A.; Deaglio, S.; Vitale, N.; Vaisitti, T. Immune response dysfunction in chronic lymphocytic leukemia: Dissecting molecular mechanisms and microenvironmental conditions. Int. J. Mol. Sci. 2020, 21, 1825. [Google Scholar] [CrossRef] [Green Version]
- Forconi, F.; Moss, P. Perturbation of the normal immune system in patients with CLL. Blood 2015, 126, 573–581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Devaud, C.; John, L.B.; Westwood, J.A.; Darcy, P.K.; Kershaw, M.H. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A.M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; Von Grünhagen, U.; et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010, 376, 1164–1174. [Google Scholar] [CrossRef]
- Fischer, K.; Bahlo, J.; Fink, A.M.; Goede, V.; Herling, C.D.; Cramer, P.; Langerbeins, P.; Von Tresckow, J.; Engelke, A.; Maurer, C.; et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 2016, 127, 208–215. [Google Scholar] [CrossRef] [Green Version]
- Beers, S.A.; Chan, C.H.T.; French, R.R.; Cragg, M.S.; Glennie, M.J. CD20 as a target for therapeutic type i and ii monoclonal antibodies. Semin. Hematol. 2010, 47, 107–114. [Google Scholar] [CrossRef] [Green Version]
- Maloney, D.G.; Smith, B.; Rose, A. Rituximab: Mechanism of action and resistance. Semin. Oncol. 2002, 29, 2–9. [Google Scholar] [CrossRef]
- Uchida, J.; Lee, Y.; Hasegawa, M.; Liang, Y.; Bradney, A.; Oliver, J.A.; Bowen, K.; Steeber, D.A.; Haas, K.M.; Poe, J.C.; et al. Mouse CD20 expression and function. Int. Immunol. 2004, 16, 119–129. [Google Scholar] [CrossRef] [Green Version]
- Sandhu, S.; Mulligan, S.P. Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia. Haematologica 2015, 100, 411–414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goede, V.; Fischer, K.; Engelke, A.; Schlag, R.; Lepretre, S.; Montero, L.F.C.; Montillo, M.; Fegan, C.; Asikanius, E.; Humphrey, K.; et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study. Leukemia 2015, 29, 1602–1604. [Google Scholar] [CrossRef] [PubMed]
- Freeman, C.L.; Gribben, J.G. Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Curr. Hematol. Malig. Rep. 2016, 11, 29–36. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goede, V.; Fischer, K.; Busch, R.; Engelke, A.; Eichhorst, B.; Wendtner, C.M.; Chagorova, T.; de la Serna, J.; Dilhuydy, M.-S.; Illmer, T.; et al. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. N. Engl. J. Med. 2014, 370, 1101–1110. [Google Scholar] [CrossRef] [Green Version]
- Lin, T.S. New Agents in Chronic Lymphocytic Leukemia. Curr. Hematol. Malig. Rep. 2010, 5, 29–34. [Google Scholar] [CrossRef]
- Shanafelt, T.D.; Wang, X.V.; Kay, N.E.; Hanson, C.A.; O’Brien, S.; Barrientos, J.; Jelinek, D.F.; Braggio, E.; Leis, J.F.; Zhang, C.C.; et al. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2019, 381, 432–443. [Google Scholar] [CrossRef] [PubMed]
- Fischer, K.; Al-Sawaf, O.; Bahlo, J.; Fink, A.-M.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med. 2019, 380, 2225–2236. [Google Scholar] [CrossRef]
- Roberts, A.W.; Davids, M.S.; Pagel, J.M.; Kahl, B.S.; Puvvada, S.D.; Gerecitano, J.F.; Kipps, T.J.; Anderson, M.A.; Brown, J.R.; Gressick, L.; et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2016, 374, 311–322. [Google Scholar] [CrossRef]
- Brusa, D.; Serra, S.; Coscia, M.; Rossi, D.; D’Arena, G.; Laurenti, L.; Jaksic, O.; Fedele, G.; Inghirami, G.; Gaidano, G.; et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 2013, 98, 953–963. [Google Scholar] [CrossRef]
- Riches, J.C.; Davies, J.K.; McClanahan, F.; Fatah, R.; Iqbal, S.; Agrawal, S.; Ramsay, A.G.; Gribben, J.G. T cells from CLLpatients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013, 121, 1612–1621. [Google Scholar] [CrossRef]
- McClanahan, F.; Riches, J.C.; Miller, S.; Day, W.P.; Kotsiou, E.; Neuberg, D.; Croce, C.M.; Capasso, M.; Gribben, J.G. Mechanisms of PD-L1/PD-1 mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model. Blood 2015, 126, 212–221. [Google Scholar] [CrossRef] [Green Version]
- Chen, L.; Han, X. Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future. J. Clin. Investig. 2015, 125, 3384–3391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, W.; LaPlant, B.R.; Call, T.G.; Parikh, S.A.; Leis, J.F.; He, R.; Shanafelt, T.D.; Sinha, S.; Le-Rademacher, J.; Feldman, A.L.; et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 2017, 129, 3419–3427. [Google Scholar] [CrossRef]
- Younes, A.; Brody, J.; Carpio, C.; Lopez-Guillermo, A.; Ben-Yehuda, D.; Ferhanoglu, B.; Nagler, A.; Ozcan, M.; Avivi, I.; Bosch, F.; et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1/2a study. Lancet Haematol. 2019, 6, e67–e78. [Google Scholar] [CrossRef]
- Jain, N.; Basu, S.; Thompson, P.A.; Ohanian, M.; Ferrajoli, A.; Pemmaraju, N.; Cortes, J.E.; Estrov, Z.; Burger, J.A.; Neelapu, S.S.; et al. Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial. Blood 2016, 128, 59. [Google Scholar] [CrossRef]
- Sagiv-Barfi, I.; Kohrt, H.E.K.; Czerwinski, D.K.; Ng, P.P.; Chang, B.Y.; Levy, R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl. Acad. Sci. USA 2015, 112, E966–E972. [Google Scholar] [CrossRef] [Green Version]
- Gökbuget, N.; Dombret, H.; Bonifacio, M.; Reichle, A.; Graux, C.; Faul, C.; Diedrich, H.; Topp, M.S.; Brüggemann, M.; Horst, H.A.; et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018, 131, 1522–1531. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nagorsen, D.; Bargou, R.; Rüttinger, D.; Kufer, P.; Baeuerle, P.A.; Zugmaier, G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma 2009, 50, 886–891. [Google Scholar] [CrossRef]
- Tian, Z.; Liu, M.; Zhang, Y.; Wang, X. Bispecific T cell engagers: An emerging therapy for management of hematologic malignancies. J. Hematol. Oncol. 2021, 14, 75. [Google Scholar] [CrossRef]
- Pianko, M.J.; Moskowitz, A.J.; Lesokhin, A.M. Immunotherapy of lymphoma and myeloma: Facts and hopes. Clin. Cancer Res. 2018, 24, 1002–1010. [Google Scholar] [CrossRef] [Green Version]
- Forconi, F.; Potter, K.N.; Wheatley, I.; Darzentas, N.; Sozzi, E.; Stamatopoulos, K.; Mockridge, C.I.; Packham, G.; Stevenson, F.K. The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 2010, 115, 71–77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chanan-Khan, A.; Miller, K.C.; Musial, L.; Lawrence, D.; Padmanabhan, S.; Takeshita, K.; Porter, C.W.; Goodrich, D.W.; Bernstein, Z.P.; Wallace, P.; et al. Clinical Efficacy of Lenalidomide in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. J. Clin. Oncol. 2006, 24, 5343–5349. [Google Scholar] [CrossRef] [PubMed]
- Itchaki, G.; Brown, J.R. Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin. Investig. Drugs 2017, 26, 633–650. [Google Scholar] [CrossRef]
- McDaniel, J.M.; Pinilla-Ibarz, J.; Epling-Burnette, P.K. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv. Hematol. 2012, 2012. [Google Scholar] [CrossRef]
- Ghosh, N.; Grunwald, M.R.; Fasan, O.; Bhutani, M. Expanding role of lenalidomide in hematologic malignancies. Cancer Manag. Res. 2015, 7, 105–119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, C.I.; Bergsagel, P.L.; Paul, H.; Xu, W.; Lau, A.; Dave, N.; Kukreti, V.; Wei, E.; Leung-Hagesteijn, C.; Li, Z.H.; et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J. Clin. Oncol. 2011, 29, 1175–1181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Badoux, X.C.; Keating, M.J.; Wen, S.; Lee, B.N.; Sivina, M.; Reuben, J.; Wierda, W.G.; O’Brien, S.M.; Faderl, S.; Kornblau, S.M.; et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118, 3489–3498. [Google Scholar] [CrossRef] [Green Version]
- Carballido, E.; Veliz, M.; Komrokji, R.; Pinilla-Ibarz, J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control 2012, 19, 54–67. [Google Scholar] [CrossRef] [Green Version]
- Badoux, X.C.; Keating, M.J.; Wen, S.; Wierda, W.G.; O’Brien, S.M.; Faderl, S.; Sargent, R.; Burger, J.A.; Ferrajoli, A. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2013, 31, 584–591. [Google Scholar] [CrossRef] [Green Version]
- Costa, L.J.; Fanning, S.R.; Stephenson, J.; Afrin, L.B.; Kistner-Griffin, E.; Bentz, T.A.; Stuart, R.K. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma 2015, 56, 645–649. [Google Scholar] [CrossRef]
- Chanan-Khan, A.; Porter, C.W. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006, 7, 480–488. [Google Scholar] [CrossRef]
- Molica, S.; Vacca, A.; Mirabelli, R.; Ria, R.; Ribatti, D. Angiogenesis in Chronic Lymphocytic Leukemia: An Emerging Target. Clin. Leuk. 2006, 1, 118–122. [Google Scholar] [CrossRef]
- Piechnik, A.; Dmoszynska, A.; Omiotek, M.; Mlak, R.; Kowal, M.; Stilgenbauer, S.; Bullinger, L.; Giannopoulos, K. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int. J. Cancer 2013, 133, 1489–1496. [Google Scholar] [CrossRef]
- Li, Y.L.; Zhao, H.; Ren, X.B. Relationship of VEGF/VEGFR with immune and cancer cells: Staggering or forward? Cancer Biol. Med. 2016, 13, 206–214. [Google Scholar] [CrossRef] [Green Version]
- Ilyas, S.; Yang, J.C. Landscape of Tumor Antigens in T Cell Immunotherapy. J. Immunol. 2015, 195, 5117–5122. [Google Scholar] [CrossRef] [Green Version]
- O’Donnell, J.S.; Teng, M.W.L.; Smyth, M.J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 2019, 16, 151–167. [Google Scholar] [CrossRef]
- Palomba, M.L. Active immunotherapy: Current state of the art in vaccine approaches for NHL. Curr. Oncol. Rep. 2012, 14, 433–440. [Google Scholar] [CrossRef]
- Slingluff, C.L. The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination? Cancer J. 2011, 17, 343–350. [Google Scholar] [CrossRef] [Green Version]
- Paston, S.J.; Brentville, V.A.; Symonds, P.; Durrant, L.G. Cancer Vaccines, Adjuvants, and Delivery Systems. Front. Immunol. 2021, 12. [Google Scholar] [CrossRef]
- Ophir, E.; Bobisse, S.; Coukos, G.; Harari, A.; Kandalaft, L.E. Personalized approaches to active immunotherapy in cancer. Biochim. Biophys. Acta Rev. Cancer 2016, 1865, 72–82. [Google Scholar] [CrossRef]
- Timmerman, J.M.; Levy, R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 1999, 50, 507–529. [Google Scholar] [CrossRef]
- Zhu, F.; Khatri, I.; Spaner, D.; Gorczynski, R.M. An autologous tumor vaccine for CLL. Leuk. Res. 2018, 68, 40–47. [Google Scholar] [CrossRef]
- Wierda, W.G.; Kipps, T.J. Gene therapy and active immune therapy of hematologic malignancies. Best Pract. Res. Clin. Haematol. 2007, 20, 557–568. [Google Scholar] [CrossRef]
- Hale, D.F.; Clifton, G.T.; Sears, A.K.; Vreeland, T.J.; Shumway, N.; Peoples, G.E.; Mittendorf, E.A. Cancer vaccines: Should we be targeting patients with less aggressive disease? Expert Rev. Vaccines 2012, 11, 721–731. [Google Scholar] [CrossRef]
- Hus, I.; Kawaik, J.; Tabarkiewicz, J.; Radej, S.; Hoser, G.; Bojarska-Junak, A.; Schmitt, M.; Giannopoulos, K.; Dmoszynska, A.; Rolinski, J. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages. Oncol. Rep. 2008, 20, 443–451. [Google Scholar] [CrossRef] [Green Version]
- Melero, I.; Gaudernack, G.; Gerritsen, W.; Huber, C.; Parmiani, G.; Scholl, S.; Thatcher, N.; Wagstaff, J.; Zielinski, C.; Faulkner, I.; et al. Therapeutic vaccines for cancer: An overview of clinical trials. Nat. Rev. Clin. Oncol. 2014, 11, 509–524. [Google Scholar] [CrossRef] [PubMed]
- Rosenberg, S.A.; Restifo, N.P.; Yang, J.C.; Morgan, R.A.; Dudley, M.E. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8, 299–308. [Google Scholar] [CrossRef] [PubMed]
- Phan, G.Q.; Rosenberg, S.A. Adoptive cell transfer for patients with metastatic melanoma: The potential and promise of cancer immunotherapy. Cancer Control 2013, 20, 289–297. [Google Scholar] [CrossRef]
- Rosenberg, S.A.; Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015, 348, 62–68. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feins, S.; Kong, W.; Williams, E.F.; Milone, M.C.; Fraietta, J.A. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am. J. Hematol. 2019, 94, S3–S9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, J.H.; Geyer, M.B.; Brentjens, R.J. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date. Blood 2016, 127, 3312–3320. [Google Scholar] [CrossRef]
- Halim, L.; Maher, J. CAR T-cell immunotherapy of B-cell malignancy: The story so far. Ther. Adv. Vaccines Immunother. 2020, 8, 251513552092716. [Google Scholar] [CrossRef] [PubMed]
- Pacenta, H.L.; Laetsch, T.W.; John, S. CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia. Pediatr. Drugs 2020, 22. [Google Scholar] [CrossRef]
- Lemal, R.; Tournilhac, O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J. Immunother. Cancer 2019, 7, 1–6. [Google Scholar] [CrossRef] [Green Version]
- Kater, A.P.; Joseph Melenhorst, J. CAR-T and ibrutinib vs CLL: Sequential or simultaneous? Blood 2020, 135, 1611–1612. [Google Scholar] [CrossRef]
- Falchi, L.; Baron, J.M.; Orlikowski, C.A.; Ferrajoli, A. BCR signaling inhibitors: An overview of toxicities associated with ibrutinib and idelalisib in patients with chronic lymphocytic leukemia. Mediterr. J. Hematol. Infect. Dis. 2016, 8, 2016011. [Google Scholar] [CrossRef] [Green Version]
- Brown, J.R.; Byrd, J.C.; Coutre, S.E.; Benson, D.M.; Flinn, I.W.; Wagner-Johnston, N.D.; Spurgeon, S.E.; Kahl, B.S.; Bello, C.; Webb, H.K.; et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014, 123, 3390–3397. [Google Scholar] [CrossRef]
- Vardi, A.; Vlachonikola, E.; Papazoglou, D.; Psomopoulos, F.; Kotta, K.; Ioannou, N.; Galigalidou, C.; Gemenetzi, K.; Pasentsis, K.; Kotouza, M.; et al. T cell dynamics in chronic lymphocytic leukemia under different treatment modalities. Clin. Cancer Res. 2020. [Google Scholar] [CrossRef]
- Mhibik, M.; Wiestner, A.; Sun, C. Harnessing the effects of BTKI on T cells for effective immunotherapy against CLL. Int. J. Mol. Sci. 2020, 21, 68. [Google Scholar] [CrossRef] [Green Version]
- Dubovsky, J.A.; Beckwith, K.A.; Natarajan, G.; Woyach, J.A.; Jaglowski, S.; Zhong, Y.; Hessler, J.D.; Liu, T.M.; Chang, B.Y.; Larkin, K.M.; et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122, 2539–2549. [Google Scholar] [CrossRef] [Green Version]
- Fraietta, J.A.; Beckwith, K.A.; Patel, P.R.; Ruella, M.; Zheng, Z.; Barrett, D.M.; Lacey, S.F.; Melenhorst, J.J.; McGettigan, S.E.; Cook, D.R.; et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 2016, 127, 1117–1127. [Google Scholar] [CrossRef] [Green Version]
- Gauthier, J.; Hirayama, A.V.; Purushe, J.; Hay, K.A.; Lymp, J.; Li, D.H.; Yeung, C.C.S.; Sheih, A.; Pender, B.S.; Hawkins, R.M.; et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 2020, 135, 1650–1660. [Google Scholar] [CrossRef]
- Hanna, B.S.; Yazdanparast, H.; Demerdash, Y.; Roessner, P.M.; Schulz, R.; Lichter, P.; Stilgenbauer, S.; Seiffert, M. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. Haematologica 2021, 106, 968–977. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gauthier, J.; Hirayama, A.V.; Hay, K.A.; Li, D.; Lymp, J.; Sheih, A.; Purushe, J.; Pender, B.S.; Hawkins, R.M.; Vakil, A.; et al. Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. Biol. Blood Marrow Transpl. 2019, 25, S9–S10. [Google Scholar] [CrossRef] [Green Version]
- Robinson, H.R.; Qi, J.; Cook, E.M.; Nichols, C.; Dadashian, E.L.; Underbayev, C.; Herman, S.E.M.; Saba, N.S.; Keyvanfar, K.; Sun, C.; et al. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood 2018, 132, 521–532. [Google Scholar] [CrossRef]
- Khadka, R.H.; Sakemura, R.; Kenderian, S.S.; Johnson, A.J. Management of cytokine release syndrome: An update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy 2019, 11, 851–857. [Google Scholar] [CrossRef] [Green Version]
- Borcoman, E.; Kanjanapan, Y.; Champiat, S.; Kato, S.; Servois, V.; Kurzrock, R.; Goel, S.; Bedard, P.; Le Tourneau, C. Novel patterns of response under immunotherapy. Ann. Oncol. 2019, 30, 385–396. [Google Scholar] [CrossRef]
- Vesely, M.D.; Schreiber, R.D. Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy. Ann. N. Y. Acad. Sci. 2013, 1284, 1–5. [Google Scholar] [CrossRef] [Green Version]
- Gajewski, T.F.; Meng, Y.; Blank, C.; Brown, I.; Kacha, A.; Kline, J.; Harlin, H. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 2006, 213, 131–145. [Google Scholar] [CrossRef]
- Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331, 1565–1570. [Google Scholar] [CrossRef] [Green Version]
- Purroy, N.; Wu, C.J. Coevolution of leukemia and hostimmunecells in chronic lymphocytic leukemia. Cold Spring Harb. Perspect. Med. 2017, 7. [Google Scholar] [CrossRef] [Green Version]
- Vlachonikola, E.; Stamatopoulos, K.; Chatzidimitriou, A. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. Front. Immunol. 2021, 11, 612244. [Google Scholar] [CrossRef]
- Roessner, P.M.; Seiffert, M. T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease? Leukemia 2020, 34, 2012–2024. [Google Scholar] [CrossRef]
- Bagnara, D.; Kaufman, M.S.; Calissano, C.; Marsilio, S.; Patten, P.E.M.; Simone, R.; Chum, P.; Yan, X.J.; Allen, S.L.; Kolitz, J.E.; et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011, 117, 5463–5472. [Google Scholar] [CrossRef]
- Zenz, T. Exhausting T cells in CLL. Blood 2013, 121, 1485–1486. [Google Scholar] [CrossRef]
- Hanna, B.S.; Roessner, P.M.; Yazdanparast, H.; Colomer, D.; Campo, E.; Kugler, S.; Yosifov, D.; Stilgenbauer, S.; Schmidt, M.; Gabriel, R.; et al. Control of chronic lymphocytic leukemia development by clonally-expanded CD8 + T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia 2019, 33, 625–637. [Google Scholar] [CrossRef]
- Scrivener, S.; Goddard, R.V.; Kaminski, E.R.; Prentice, A.G. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma 2003, 44, 383–389. [Google Scholar] [CrossRef]
- Gonzalez-Rodriguez, A.P.; Contesti, J.; Huergo-Zapico, L.; Lopez-Soto, A.; Fernández-Guizn, A.; Acebes-Huerta, A.; Gonzalez-Huerta, A.J.; Gonzalez, E.; Fernandez-Alvarez, C.; Gonzalez, S. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk. Lymphoma 2010, 51, 1829–1836. [Google Scholar] [CrossRef]
- Nunes, C.; Wong, R.; Mason, M.; Fegan, C.; Man, S.; Pepper, C. Expansion of a CD8 +PD-1 + replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin. Cancer Res. 2012, 18, 678–687. [Google Scholar] [CrossRef] [Green Version]
- Göthert, J.R.; Eisele, L.; Klein-Hitpass, L.; Weber, S.; Zesewitz, M.L.; Sellmann, L.; Röth, A.; Pircher, H.; Dührsen, U.; Dürig, J. Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype. Cancer Immunol. Immunother. 2013, 62, 1697–1709. [Google Scholar] [CrossRef]
- Buschle, M.; Campana, D.; Carding, S.R.; Richard, C.; Victor Hoffbrand, A.; Brenner, M.K. Interferon γ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J. Exp. Med. 1993, 177, 213–218. [Google Scholar] [CrossRef]
- Catakovic, K.; Gassner, F.J.; Ratswohl, C.; Zaborsky, N.; Rebhandl, S.; Schubert, M.; Steiner, M.; Gutjahr, J.C.; Pleyer, L.; Egle, A.; et al. TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology 2018, 7. [Google Scholar] [CrossRef]
- Wong, R.; Pepper, C.; Brennan, P.; Nagorsen, D.; Man, S.; Fegan, C. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 2013, 98, 1930–1938. [Google Scholar] [CrossRef] [Green Version]
- Baeuerle, P.A.; Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009, 69, 4941–4944. [Google Scholar] [CrossRef] [Green Version]
- Corral-Jara, K.F.; Rosas da Silva, G.; Fierro, N.A.; Soumelis, V. Modeling the Th17 and Tregs Paradigm: Implications for Cancer Immunotherapy. Front. Cell Dev. Biol. 2021, 9, 1147. [Google Scholar] [CrossRef]
- Piper, K.P.; Karanth, M.; McLarnon, A.; Kalk, E.; Khan, N.; Murray, J.; Pratt, G.; Moss, P.A.H. Chronic lymphocytic leukaemia cells drive the global CD4 + T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4 + forkhead box P3 + T cells. Clin. Exp. Immunol. 2011, 166, 154–163. [Google Scholar] [CrossRef]
- Hus, I.; Bojarska-Junak, A.; Chocholska, S.; Tomczak, W.; Wos, J.; Dmoszyn, A.; Rolin, J. Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity. PLoS ONE 2013, 8, 78091. [Google Scholar] [CrossRef] [Green Version]
- Jadidi-Niaragh, F.; Ghalamfarsa, G.; Memarian, A.; Asgarian-Omran, H.; Razavi, S.M.; Sarrafnejad, A.; Shokri, F. Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. Tumor Biol. 2013, 34, 929–940. [Google Scholar] [CrossRef] [PubMed]
- Duell, J.; Dittrich, M.; Bedke, T.; Mueller, T.; Eisele, F.; Rosenwald, A.; Rasche, L.; Hartmann, E.; Dandekar, T.; Einsele, H.; et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 2017, 31, 2181–2190. [Google Scholar] [CrossRef]
- Munegowda, M.A.; Deng, Y.; Mulligan, S.J.; Xiang, J. Th17 and Th17-stimulated CD8 + T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol. Immunother. 2011, 60, 1473. [Google Scholar] [CrossRef]
- Khodadoust, M.S.; Olsson, N.; Chen, B.; Sworder, B.; Shree, T.; Liu, C.L.; Zhang, L.; Czerwinski, D.K.; Davis, M.M.; Levy, R.; et al. B-cell lymphomas present immunoglobulin neoantigens. Blood 2019, 133, 878–881. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Chen, L.; Zhang, L.; Yu, J.; Rassenti, L.Z.; Kipps, T.J. Human ROR1 Activates AKT and Accelerates Leukemia Cell Proliferation. Blood 2012, 120, 3872. [Google Scholar] [CrossRef]
- Kipps, T.; Rassenti, L.Z.; Widhopf, G.F., II; Kipps, T.J. Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells. Blood 2018, 132, 4404. [Google Scholar] [CrossRef]
- Hudecek, M.; Schmitt, T.M.; Baskar, S.; Lupo-Stanghellini, M.T.; Nishida, T.; Yamamoto, T.N.; Bleakley, M.; Turtle, C.J.; Chang, W.C.; Greisman, H.A.; et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010, 116, 4532–4541. [Google Scholar] [CrossRef] [Green Version]
- Sherman, W.; Liu, Z.; Inghirami, G.; Reed, E.F.; Harris, P.E.; Suciu-Foca, N.M. Major histocompatibility complex-restricted recognition of autologous chronic lymphocytic leukemia by tumor-specific T cells. Immunol. Res. 1993, 12, 338–348. [Google Scholar] [CrossRef]
- Billadeau, D.D.; Nolz, J.C.; Gomez, T.S. Regulation of T-cell activation by the cytoskeleton. Nat. Rev. Immunol. 2007, 7, 131–143. [Google Scholar] [CrossRef]
- Görgün, G.; Holderried, T.A.W.; Zahrieh, D.; Neuberg, D.; Gribben, J.G. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J. Clin. Investig. 2005, 115, 1797–1805. [Google Scholar] [CrossRef]
- Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgün, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Investig. 2008. [Google Scholar] [CrossRef]
- Sabrina Bertilaccio, M.T.; Tettamanti, S.; Giordano Attianese, G.M.P.; Galletti, G.; Arcangeli, S.; Rodriguez, T.V.; Magnani, C.F.; Barbaglio, F.; Scarfò, L.; Ponzoni, M.; et al. Low-Dose Lenalidomide Improves CAR-Based Immunotherapy in CLL By Reverting T-Cell Defects In Vivo. Blood 2013, 122, 4171. [Google Scholar] [CrossRef]
- Poh, C.; Frankel, P.; Ruel, C.; Abedi, M.; Schwab, E.; Costello, C.L.; Zain, J.; Budde, L.E.; William, B.M.; Foss, F.M.; et al. Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin’s Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood 2019, 134, 760. [Google Scholar] [CrossRef]
- Wherry, E.J. T cell exhaustion. Nat. Immunol. 2011, 12, 492–499. [Google Scholar] [CrossRef] [PubMed]
- Palma, M.; Gentilcore, G.; Heimersson, K.; Mozaffari, F.; Näsman-Glaser, B.; Young, E.; Rosenquist, R.; Hansson, L.; Österborg, A.; Mellstedt, H. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 2017, 102, 562–572. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Y.; Shao, Q.; Peng, G. Exhaustion and senescence: Two crucial dysfunctional states of T cells in the tumor microenvironment. Cell. Mol. Immunol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Kasakovski, D.; Xu, L.; Li, Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J. Hematol. Oncol. 2018, 11, 1–9. [Google Scholar] [CrossRef]
- Crespo, J.; Sun, H.; Welling, T.H.; Tian, Z.; Zou, W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 2013, 25, 214–221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poorebrahim, M.; Melief, J.; Pico de Coaña, Y.; Wickström, S.L.; Cid-Arregui, A.; Kiessling, R. Counteracting CAR T cell dysfunction. Oncogene 2021, 40, 421–435. [Google Scholar] [CrossRef] [PubMed]
- Xia, A.; Zhang, Y.; Xu, J.; Yin, T.; Lu, X.J. T Cell Dysfunction in Cancer Immunity and Immunotherapy. Front. Immunol. 2019, 10, 1719. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wen, T.; Mellstedt, H.; Jondal, M. Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J. Exp. Med. 1990, 171, 659–666. [Google Scholar] [CrossRef] [Green Version]
- Vardi, A.; Agathangelidis, A.; Stalika, E.; Karypidou, M.; Siorenta, A.; Anagnostopoulos, A.; Rosenquist, R.; Hadzidimitriou, A.; Ghia, P.; Sutton, L.-A.; et al. Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia. Clin. Cancer Res. 2016, 22, 167–174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vardi, A.; Vlachonikola, E.; Karypidou, M.; Stalika, E.; Bikos, V.; Gemenetzi, K.; Maramis, C.; Siorenta, A.; Anagnostopoulos, A.; Pospisilova, S.; et al. Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: High-throughput immunoprofiling supports selection by shared antigenic elements. Leukemia 2017, 31, 1555–1561. [Google Scholar] [CrossRef]
- Kowalewski, D.J.; Schuster, H.; Backert, L.; Berlin, C.; Kahn, S.; Kanz, L.; Salih, H.R.; Rammensee, H.G.; Stevanovic, S.; Stickel, J.S. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc. Natl. Acad. Sci. USA 2015, 112, E116–E175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vlachonikola, E.; Stamatopoulos, K.; Chatzidimitriou, A. T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers 2021, 13, 3255. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13133255
Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers. 2021; 13(13):3255. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13133255
Chicago/Turabian StyleVlachonikola, Elisavet, Kostas Stamatopoulos, and Anastasia Chatzidimitriou. 2021. "T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia" Cancers 13, no. 13: 3255. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13133255